专家热议如何完善创新药价格形成机制，助力产业高质量发展

Group 1 - The seminar focused on improving the drug pricing mechanism to support the high-quality development of the innovative drug industry in China [1][8] - The State Council approved the "Implementation Plan for Supporting the Development of Innovative Drugs," providing systematic guidance for R&D, approval, pricing, and payment processes [5] - The innovative drug sector is transitioning from "catching up" to "running alongside," with a stable pricing system and improved clinical application efficiency, but still faces challenges such as an imperfect return mechanism and risks in capital and technology collaboration [5][6] Group 2 - Experts emphasized the need for dynamic pricing adjustments based on the lifecycle value of drugs, with initial clinical value assessments and strategies to cope with generic competition [6][7] - International experiences from countries like the US, Germany, and Japan can help refine China's innovative drug pricing mechanism, highlighting the need for a collaborative government-market approach [6][7] - Suggestions were made to expand commercial health insurance coverage in public medical institutions and enhance data interoperability to support risk assessment [7] Group 3 - The seminar was organized by the Policy Research Committee of the China Pharmaceutical News Information Association, which plays a crucial role in promoting pharmaceutical policy research and communication [8] - The committee aims to summarize the seminar's outcomes and provide decision-making references for national policy formulation to foster industry development [8]